The impact of initial statin treatment decisions on cardiovascular outcomes in clinical care settings: estimates using the Archimedes Model

References

• MackayJMensahGAThe Atlas Of Heart Disease And StrokeGenevaWorld Health Organization2004 Available from: http://www.who.int/cardiovascular_diseases/resources/atlas/en/Accessed January 20, 2012
   Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation2004110222723915249516
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet200536694931267127816214597
   PubMed Web of Science ®Google Scholar
• WilleyVJBullanoMFShoetanNNGandhiSKTherapy modifications and low-density lipoprotein cholesterol goal attainment rates associated with the initiation of generic simvastatinCurr Med Res Opin201026112112819916706
   PubMed Web of Science ®Google Scholar
• WatersDDBrotonsCChiangCWLipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goalsCirculation20091201283419546386
   PubMed Web of Science ®Google Scholar
• EddyDMSchlessingerLValidation of the archimedes diabetes modelDiabetes Care200326113102311014578246
   PubMed Web of Science ®Google Scholar
• EddyDMSchlessingerLArchimedes: a trial-validated model of diabetesDiabetes Care200326113093310114578245
   PubMed Web of Science ®Google Scholar
• National Health and Nutrition Examination Survey data 1999–2006[webpage on the Internet]Atlanta, GACenters for Disease Control and Prevention [updated June 19, 2012]. Available from: http://www.cdc.gov/nchs/nhanes.htmAccessed January 20, 2012
   Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• PedersenTRFaergemanOKasteleinJJHigh-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trialJAMA2005294192437244516287954
   PubMed Web of Science ®Google Scholar
• ColhounHMBetteridgeDJDurringtonPNPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet2004364943568569615325833
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med2005352141425143515755765
   PubMed Web of Science ®Google Scholar
• SchlessingerLEddyDMArchimedes: a new model for simulating health care systems – the mathematical formulationJ Biomed Inform2002351375012415725
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA2001285192486249711368702
   PubMed Web of Science ®Google Scholar
• United States Department of Health and Human ServicesJNC 7 Express: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureBethesda, MDNational Institutes of Health2003
   Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200831117317518165348
   PubMed Web of Science ®Google Scholar
• SchuetzCAvan HerickAAlperinPPeskinBHsiaJGandhiSComparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes ModelJ Med Econ6202012 [Epub ahead of print.]
   Google Scholar
• JonesPHDavidsonMHSteinEAComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol200392215216012860216
   PubMed Web of Science ®Google Scholar
• AltmanDGAndersenPKCalculating the number needed to treat for trials where the outcome is time to an eventBMJ199931972231492149510582940
   PubMed Web of Science ®Google Scholar
• JonesPHStatins: the case for higher, individualized starting dosesCleve Clin J Med200572981181616193828
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med2004350151495150415007110
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFARosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med2008359212195220718997196
   PubMed Web of Science ®Google Scholar
• SeverPSDahlofBPoulterNRPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet200336193641149115812686036
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent Events Trial investigatorsN Engl J Med1996335100110098801446
   PubMed Web of Science ®Google Scholar